VTE incidence and risk factors in patients with severe sepsis and septic shock

Chest

Volumn 148, Issue 5, 2015, Pages 1224-1230

  Kaplan, David ^a   Charles Casper, T ^b   Gregory Elliott, C ^d   Men, Shaohua ^b   Pendleton, Robert C ^c   Kraiss, Larry W ^a   Weyrich, Andrew S ^a,c   Grissom, Colin K ^a,d   Zimmerman, Guy A ^a   Rondina, Matthew T ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Study Design and Biostatistics Center   (United States)

^c Molecular Medicine Program   (United States)

^d INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HYPERTENSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGE; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR DISEASE; CENTRAL VENOUS CATHETERIZATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ECHOGRAPHY; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; OBESITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SEPTIC SHOCK; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; COMPLICATION; PROCEDURES; RISK ASSESSMENT; SURVIVAL RATE; TRENDS; UTAH;

FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEPSIS; SHOCK, SEPTIC; SURVIVAL RATE; UTAH; VENOUS THROMBOEMBOLISM;

EID: 84946606807     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0287     Document Type: Article

References (23)

1. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med. 2001; 161 (10): 1268-1279.
2. Cook D, Attia J, Weaver B, McDonald E, Meade M, Crowther M. Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care. 2000; 15(4): 127-132.
3. Ribic C, Lim W, Cook D, Crowther M. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. J Crit Care. 2009; 24 (2): 197-205.
4. Marik PE, Andrews L, Maini B. The incidence of deep venous thrombosis in ICU patients. Chest. 1997; 111 (3): 661-664.
5. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. 1995; 274 (4): 335-337.
6. Twigg SJ, McCrirrick A, Sanderson PM. A comparison of post mortem findings with post hoc estimated clinical diagnoses of patients who die in a United Kingdom intensive care unit. Intensive Care Med. 2001; 27 (4): 706-710.
7. Cook D, McMullin J, Hodder R, et al; Canadian ICU Directors Group. Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey. Crit Care. 2001; 5 (6): 336-342.
8. Lacherade JC, Cook D, Heyland D, Chrusch C, Brochard L, Brun-Buisson C; French and Canadian ICU Directors Groups. Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study. J Crit Care. 2003; 18 (4): 228-237.
9. Cook D, Meade M, Guyatt G, et al; Canadian Critical Care Trials Group. Clinically important deep vein thrombosis in the intensive care unit: a survey of intensivists. Crit Care. 2004; 8 (3): R145-R152.
10. Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medicalsurgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005; 33 (7): 1565-1571.
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20 (6): 864-874.
12. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41 (2): 580-637.
13. Talbot SR. B-mode evaluation of peripheral veins. Semin Ultrasound CT MR. 1988; 9 (4): 295-319.
14. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9Thed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2-suppl):e195S-e226S.
15. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9Thed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2-suppl):e419S-e494S.
16. Muscedere JG, Heyland DK, Cook D. Venous thromboembolism in critical illness in a community intensive care unit. J Crit Care. 2007; 22 (4): 285-289.
17. Rondina MT, Carlisle M, Fraughton T, et al. Platelet-monocyte aggregate formation and mortality risk in older patients with severe sepsis and septic shock. J Gerontol A Biol Sci Med Sci. 2015;70(2): 225-231.
18. Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res. 2013; 112 (11): 1506-1519.
19. Rondina MT, Brewster B, Grissom CK, et al. In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest. 2012; 141 (6): 1490-1495.
20. Rondina MT, Schwertz H, Harris ES, et al. The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost. 2011; 9 (4): 748-758.
21. Harris ES, Rondina MT, Schwertz H, Weyrich AS, Zimmerman GA. Pathogenesis of sepsis and sepsis-induced acute lung injury. In: Choi AMK, ed. Acute Respiratory Distress Syndrome. New York, NY: Informa Healthcare; 2010: 369-419.
22. Levi M. The coagulant response in sepsis and inflammation. H amostaseologie. 2010; 30 (1): 10-12, 14-16.
23. Evans RS, Sharp JH, Linford LH, et al. Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest. 2010; 138 (4): 803-810.